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Tomasz Urasiński 9, Renata Tomaszewska 10, Tomasz Szczepański 10,
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Background: The aim of the study was to analyze the treatment outcome and genetic
characteristics of acute promyelocytic leukemia (APL) in children in Poland from 2005
to 2018.
Methods: All 41 patients diagnosed with APL in Poland during the analysis period were
eligible for the study. In period I (2005–2015), 33 patients were treated with chemotherapy
and all-trans retinoic acid (ATRA), and in period II (2015–2018), 3 patients (high risk)
received induction chemotherapy with ATRA and arsenic trioxide (ATO), and 5 patients
(standard risk) received ATRA and ATO without chemotherapy.
Results: Probability of 5-years overall survival (OS), event-free survival (EFS), and
relapse-free survival (RFS) was 0.819 ± 0.069, 0.831 ± 0.063, and 0.961 ± 0.037,
respectively, in the whole cohort. Four (11%) early deaths were observed. One patient
died of severe infection in the course of disease progression. Relapse occurred in one
patient, who died finally because of disease progression. All events occurred in the
patients from period I. Variant APL was identified in one patient (successfully treated with
chemotherapy with ATRA) and complex translocation in one patient (the only patient
with relapse). Additional chromosomal aberrations were found in 26% of patients and
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FLT3-ITD mutation was detected in 44% of patients; none of those changes influenced
clinical outcome.
Conclusion: Treatment outcome in the analyzed group is similar to the results reported
by other study groups. The main cause of death was coagulation disorders in the early
stage of disease. Early, accurate diagnosis followed by specific treatment enables the
reduction in the number of early deaths.
Keywords: acute promyelocytic leukemia, children, variant translocations, treatment results, ATO, ATRA
INTRODUCTION
Acute promyelocytic leukemia (APL) is a specific subtype of acute
myeloid leukemia (AML). In most cases, it is characterized by
translocation (15;17) with the PML-RARA fusion gene (1–3), but
about 1–2% of APL cases are due to rare variant translocations
including ZBTB16/RARA, NMP/RARA, NUMA/RARA,
STAT5B/RARA, PRKAR1a/RARA, BCOR/RARA, and
FIP1L1/RARA (4–6). APL comprises about 5–10% of pediatric
AML (1) and about 0.4% of all malignancies in children.
Methods of the treatment used in children are based on clinical
studies performed on greater adult population. Until the late
1980’s, APL was the most lethal subtype of AML (2, 3). The
result of the treatment improved significantly since the 1980’s
when specific treatment with all-trans retinoic acid (ATRA)
was introduced (2, 3, 7–9). Since the 1990’s, another specific
drug—arsenic trioxide (ATO)—has been implemented. Efficacy
and safety were first proven in adult patients (10–12) followed
by the studies in children (1, 13–16). The combination of ATRA,
ATO, and anthracycline-based chemotherapy ensures remission
achievement in almost all patients (1, 13–16). Use of the specific
treatment in APL allowed reduction of the chemotherapy
especially cumulative anthracycline doses (13, 15–17). The main
causes of the treatment failure are still early deaths, mostly in
the course of intracranial hemorrhage (2, 3, 18). In the large
analysis comprising 683 patients from different international
studies, initial high WBC counts and obesity were found as likely
predictors of thrombohemorrhagic early deaths in childhood
APL (18).
Here, we present retrospective analysis of the treatment results
of pediatric APL in Poland from 2005, when genetic analysis
became widely available to confirm diagnosis of APL, to 2018.
Children were treated according to two consecutive protocols,
first (2005–2015) based on combination of chemotherapy and
ATRA and second (2015–2018) based on ATRA and ATO with
or without chemotherapy depending on number of leukocytes
at diagnosis.
The aims of the study were to assess clinical outcome and
determine the causes of treatment failures. We also performed
analysis of additional genetic changes found in APL patients.
PATIENTS AND METHODS
From January 2005 to December 2018, 41 children (age 0–
18) with newly diagnosed APL were treated in 16 centers of
the Polish Pediatric Leukemia and Lymphoma Study Group.
They comprised 6.5% of all 627 pediatric patients diagnosed
with AML in that period. They were treated according to two
consecutive protocols (AML-BFM 2004 Interim and AML-BFM
2012). Patient characteristics are summarized in Table 1. All of
them were eligible for the study. The last patient was enrolled in
May 2018 and the last follow-up was done in December 2018.
Median observation time was 61.7 months (range, 7.0–145.5
months). The data were collected in Polish AML registry and
analyzed retrospectively.
Informed consent to participation in the studies was obtained
from guardians of all patients, in accordance with the Declaration
of Helsinki. The study was approved by the Ethics Committee of
Jagiellonian University Medical College.
All patients with characteristic bone marrow morphology
and immunophenotype had diagnosis confirmed by the use
of conventional cytogenetics, showing t(15;17) or variant
translocations, and/or by fluorescence in situ hybridization
tests for PML/RARa fusion or positive reverse transcription
polymerase chain reaction (RT-PCR) assay.
The FLT3-ITD mutation analyses were routinely performed
in all children. Patients were also screened for additional
chromosomal aberrations.
In the first period (January 2005–June 2015, period I) 33
patients were treated according to AML-BFM 2004 Interim
Protocol; in the second period (July 2015–December 2018,
period II) 8 children were treated according to AML-BFM 2012
Protocol. In period I, treatment consisted of four intensive
chemotherapy cycles (AIE: cytarabine, idarubicine, etoposide,
AI: cytarabine, idarubicine, haM: high-dose cytarabine,
mitoxantron, HAE: high-dose cytarabine, etoposide; additional
intrathecal cytarabine in every cycle) and maintenance











Age, years 12.4 12.34 13.51
median (range) (0.1–17.9) (0.1–17.9) (3.7–17.8)
Gender Males 21 (51%) 18 (54.5%) 3 (37%)
Females 20 (49%) 15 (45.5%) 5 (63%)
Observation time, months 61.7 61.7 18.4
median (range) (7.0–145.5) (12.7–145.5) (7.0–30.0)
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FIGURE 1 | First period (AML-BFM 2004 Interim) treatment scheme. AIE—cytarabine 100 mg/m2/day [days 1–2] and 100 mg/m2 every 12 h [days 3–8], idarubicin 12
mg/m2/day [days 3, 5, and 7], and etoposide 150 mg/m2/day [days 6–8]. AI—cytarabine 500 mg/m2/day [days 1–4] and idarubicin 7.5 mg/m2/day [days 3 and 5].
haM—cytarabine 1 g/m2 every 12 h [days 1–3] and mitoxantrone 7 mg/m2/day [days 3–4]. HAE—cytarabine 3 g/m2/every 12 h [days 1–3], etoposide 125 mg/m2/day
[days 2–5]. Maintenance chemotherapy—lasting 1 year: thioguanine 40 mg/m2/day orally, cytarabine 40 mg/m2/day intravenously for 4 consecutive days, every 4
weeks. ATRA—all trans-retinoid acid 25 mg/m2/day for 14 days. Intrathecal cytarabine in the age-depended dose (<1 year 20mg; 1–2 years 26mg; 2–3 years 34mg;
>3 years 40mg) in each chemotherapy cycle and during maintenance treatment. CNS, central nervous system.
therapy (6-thioguanine, cytarabine) for 1 year. All patients
received ATRA concomitant with chemotherapy in 14-days
cycles (Figure 1). Median observation time was 61.7 months
(12.7–145 months).
In period II, according to the AML-BFM 2012 Protocol,
patients with APL were classified into two groups according
to initial number of white blood cells (WBC). There were five
patients in the standard risk (SR) group with initial WBC
<10,000/µl treated with the ATRA and ATO regimen. Three
other patients were in the high-risk (HR) group (WBC more
than 10.000/µl), and received one chemotherapy cycle (AI:
cytarabine, idarubicine) with ATRA andATO (Figure 2). Median
observation time was 18.4 months (range, 7.0–30 months).
Molecular response was assessed centrally according to
Europe Against Cancer program (19). It was monitored in period
II, while the data from period I are very limited (complete data
from 1 patient and two results in 5 patients−15 and 24 months
from diagnosis). In period II and in 1 patient from period I,
molecular minimal residual disease (MRD) was monitored on
days 21, 56, 84, and 112 from the beginning of the treatment
and then every 3 months for 12 months in the SR group and 18
months in the HR group.
In our database, we also collected data about differentiation
syndrome (DS), severe adverse effect of ATO, and long-lasting
consequences of the treatment in patients observed for at least
18 months. DS was defined as having at least three of the
following symptoms: unexplained fever, weight gain, dyspnea,
and pulmonary infiltrates.
The data that support the findings of the study are available on
request from the corresponding author. The data are not publicly
available due to privacy or ethical restrictions.
Statistical Analysis
Descriptive statistical analysis was performed to assess patient
baseline characteristics. We used Fisher’s exact test or a chi-
square test (categorical variables) and Mann–Whitney test
(continuous variables) for analysis of clinical and laboratory
features. Early mortality was defined as death within 42 days of
the induction therapy. Overall survival (OS), event-free survival
(EFS), and disease-free survival (DFS) were calculated using the
Kaplan–Meier method. OS was defined as the time diagnosis
to death from any cause; patients alive or lost to follow-up
were censored at the date they were last known alive. EFS
was defined as the time from diagnosis to disease progression,
relapse, or death from any cause. Patients who were alive without
disease progression or relapse were censored at the last time
they were seen alive and event-free. DFS was defined as the
time from complete remission (CR) to disease relapse, or death
from any cause. Patients who were alive without disease relapse
were censored at the time of last follow-up. For comparisons of
Kaplan–Meier curves, we used the log-rank test. Because there
were just eight patients in period II and observation time was
much shorter than that in period I, we did not perform any
statistical analysis to compare these two periods. All statistical
analyses were performed using STATISTICA 12 software.
RESULTS
Genetic Aberrations
In 27 patients (65.8%), complete cytogenetic analysis was
available. Variant APL with t(11;17) (q23;q12) was identified in
one patient and complex translocation involving chromosomes
4, 15, 16, and 17 in another patient (Table 2).
Additional chromosomal aberrations were found in seven
patients (26% of 27 patients with available karyotype results).
We identified the trisomy of chromosome 8 in three patients,
derivated chromosome 8 in one patient, complex karyotype
in two patients (involving chromosomes 3 and 9 with marker
chromosome in one patient and involving chromosome 6
with two marker chromosomes in one patient), and additional
material from chromosome 16 in the above-described patient
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FIGURE 2 | Second period (AML-BFM 2012) treatment scheme. AI—cytarabine 100 mg/m2/day [days 1–2] and 100 mg/m2 every 12 h [days 3–8], idarubicin 12
mg/m2/day [days 3, 5, and 7]. ATRA—all trans-retinoid acid 25 mg/m2/day oral in two divided doses for 14 days. ATO—arsentrioxide 0.15 mg/kg/day, starting at day
10 until morphologic CR, after 2 weeks brake: 4 cycles Monday–Friday 0.15 mg/kg/day i.v. for 4 weeks and 4 weeks break. MRD, minimal residual disease; i.th.,
intrathecal cytarabine in the age-depended dose (<1 year 20mg; 1–2 years 26mg; 2–3 years 34mg; >3 years 40mg). CR, complete remission.
with complex translocation involving chromosomes 4, 15, 16,
and 17 (Table 2).
Result of FLT3-ITD mutation analysis was available in 32
(78%) patients. This mutation was detected in 14 patients (44%).
Treatment Response and the Treatment
Failures
Thirty six (88%) patients achieved complete hematological
remission. Data concerning molecular response were available in
nine patients (one from period I and eight from period II). On
day 21, molecular MRD was negative in two of seven patients
with available result, and on day 56, it was negative in seven
of eight patients with available results from that time point. All
nine patients with available molecular monitoring had negative
MRD results from day 84. No molecular relapse occurred. Four
(9.7%) early deaths (5–10 days from diagnosis) caused by severe
coagulation disorders were observed. Nine patients (21.9%)
suffered from severe bleedings including those four children
who died. One patient (2.4%) died of severe infection in the
course of disease progression 1.9 months after diagnosis (no data
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Complications Outcome Observation time
(months)










3 45-47, XX,−6, add (6)(p25),
t(5,17)(q22;q21),+mar, +mar
(7)/46XX,PML/RARA(+),MLL(–),FLT3-ITD(–)




4 47,XX, +8, t(15;17)(q22;q21); PML/RARA(+)
FLT3-ITD(–),





1–5 0.45 20 - Alive 56.6
6 47XX,+8,t(15,17)(q22,q21) 10–15 2.0 187 ATRA syndrome Alive 83.6
7 46,XY, t(15,17)(q22,q21)[9]/47XY+8;
FLT3-ITD(–)




13 20.0 24 - Alive 61.7
WBC, number of white blood cells at diagnosis; PLT, number of platelets at diagnosis; ND, no data; DIC, disseminated intravascular coagulation; ATRA, all trans-retinoic acid.











1 10–15 40 26 46,XX,t(15;17)(q22;q21), PML/RARA(+),
FLT3-ITD(+)
Early death (DIC, MOF) 0.17 0.17
2 1–5 151 0 PML/RARA (+), FLT3-ITD (+) Early death (intracranial
bleeding)
0.2 0.2
3 10–15 92 30 46,XY,t(15;17), FLT3-ITD non-available Early death (intracranial
bleeding)
0.3 0.3






Relapse, death in progression
after second relapse
17.3 37.7
5 10–15 24 6 46,XY,t(15;17), FLT3-ITD(–) Death in progression 0 1.87
6 1–5 196 21 PML/RARA (+), FLT3-ITD analysis
non-available
Early death (DIC, leukostasis) 0.33 0.33
DIC, disseminated intravascular coagulation; MOF, multiorgan failure; WBC, number of white blood cells at diagnosis; PLT, number of platelets at diagnosis; EFS, event-free survival;
OS, overall survival.
concerning molecular MRD were available). Relapse occurred in
one patient (2.4%), 17months after first hematological remission.
That was the patient with complex translocation. The patient
did not respond to second-line chemotherapy (Idarubicine,
Fludarabine) with ATRA, but achieved hematological remission
after ATO treatment, followed by hematopoietic stem cell
transplantation (HSCT). Fourteen months after HSCT, second
relapse confirmed by molecular examination occurred, and the
patient died 2 months later despite second-line therapy because
of disease progression. No data concerning molecular response
are available in that patient. Table 3 displays characteristics of
the patients with the treatment failures. All events occurred
in the patients from period I. There was no event in patients
diagnosed after 2011 (21/41 children, 51%). Treatment results in
two periods are presented in Table 4.
Analysis of Survival
The probability of 5-years OS, EFS, and RFS was 0.832 ± 0.069,
0.848 ± 0.066, and 0.964 ± 0.035, respectively, for all analyzed
patients (Figure 3).
White blood cell count at diagnosis was significantly higher in
children who died early compared to the other patients (median
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[range]: 121 × 103/µl [40–196 × 103/µl] vs. 5.2 × 103/µl
[0.45–140× 103/µl], p= 0.003).
Patients with more than 10,000/µl WBC at diagnosis had
significantly lower probability of 5-years OS and EFS compared
to patients with WBC <10,000/µl at diagnosis (1.0 vs. 0.63, p =
0.004 and 1.0 vs. 0.67, p= 0.005, respectively) (Figure 4).
The time from diagnosis to ATRA introduction did not
differ between patients with treatment failure and other patients
[median (range): 2 (1–4) days vs. 3 (0–56 days) p= 0.67].
There was no significant difference in OS, EFS, and DFS
between patient FLT3-ITD positive and FLT3-ITD negative.
Among 14 FLT3-ITD-positive patients, two early deaths occurred
(14.3%), compared to 1 early death (5.5%), 1 progression (5.5%),
and 1 relapse (5.5%) in 18 FLT3-ITD-negative patients. Number













36 (87.8) 28 (84.8) 8 (100)
Early deaths (%) 4 (9.7) 4 (12.2) 0
Death in progression (%) 1 (2.4) 1 (3) 0
Relapse (%) 1 (2.4) 1 (3) 0
Continuous CR (%) 35 (85.3) 27 (81.8) 8 (100)
Severe bleedings (%) 9 (21.9) 8 (24.2) 1 (12.5)
of WBC at diagnosis did not differ significantly in patients
with and without FLT3-ITD mutation (median [range]: 18.2 ×
109/L [0.9–150.7 × 109/L] vs. 6.5 × 109/L [0.4–140 × 109/L],
respectively, p= 0.4).
Patients with additional chromosomal aberrations did not
differ significantly from patients without those aberrations
in terms of survival rates (OS, EFS, and RFS). The only
event occurred in the patient with complex translocation and
additional material from chromosome 16 who had two relapses
and died of the disease progression 36.7 months after diagnosis.
The patient with variant translocation (11;17) was treated
successfully with a combination of chemotherapy and ATRA and
remains in remission with an observation time of 4 years.
Adverse Events of ATRA and ATO
DS was observed in 29% of patients (9/31, no data from 10
patients), eight of whom were treated with steroids; in three
patients, ATRA was held and then restarted.
There were no severe adverse events in patients treated with
ATO. Transient rash occurred in one patient at the beginning of
the therapy.
Late Consequences of the Treatment
Data concerning long-lasting consequences of the treatment were
available in 23 of 34 patients with an observation time of at least
18 months. One patient was diagnosed with aseptic bone necrosis
and one was diagnosed with ischemic stroke of brain. We did not
find any long-lasting toxicities in 21 patients (91%).
FIGURE 3 | Probability of overall, event-free, and relapse-free survival in all analyzed patients with APL. APL, acute promyelocytic leukemia; OS, overall survival; EFS,
event-free survival; RFS, relapse-free survival.
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FIGURE 4 | Probability of overall and event-free survival depending on number of WBC at diagnosis. OS, overall survival; EFS, event-free survival; WBC, white blood
cell number at diagnosis.
DISCUSSION
APL comprises about 5–10% of childhood acute myeloid
leukemia (1). In the analyzed period, the percentage of the
patients with APL among all children with AML in Poland
was 6.5%. The treatment results achieved in the study group
(OS, 0.832 ± 0.069; EFS, 0.848 ± 0.066; RFS, 0.964 ± 0.035)
are comparable to the results described by other authors (1, 2,
7, 8, 13, 16, 17); however, the number of enrolled patients is
relatively low. The data concerning molecular monitoring were
limited in period I so comparison between two groups was
not possible.
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The bleeding complications remain the main cause of the
treatment failures in APL. They were found in 4 (9.7%) patients
in our cohort. It is worth noticing that there was no early
death in patients with APL in Poland from 2011. It seems that
early introduction of ATRA/ATO as well as oncology centers
experience reduced the risk of early deaths. New treatment
protocol introduced in 2015 with reduction of chemotherapy and
use of ATO seems to be very effective. There were no events
in that period; however, follow-up was rather short (median
18.4 months).
Variant translocation described as simple translocation
involving chromosome 15 or 17 with any other chromosomes
or complex translocations characterized by the involvement of
additional chromosomes in addition to chromosomes 15 and 17
(4–6, 20–24) was found in two patients in the analyzed group.
In one of them, t(11;17) (q23;q12) was identified, and in the
second complex, translocation involving chromosomes 4, 15,
16, and 17 was found. The first patient was treated successfully
with combination of chemotherapy and ATRA and remains
in remission with an observation time of 4 years. The patient
with complex translocation died of disease progression after
second relapse.
Two different variant APL translocations involving
chromosomes 11 and 17 were described before, t(11;17)(q23;q21)
producing ZBTB16-RARA (formerly PLZF-RARA) fusion gene
and t(11;17)(q13;q21) generating NUMA/RARA (20, 22).
In cases of APL with t(11;17)(q23q21), there is evidence
of resistance to ATRA and ATO both in vivo and in vitro,
particularly in those patients who have the reverse rearrangement
RARα-PLZF (20), while patients with t(11;17)(q13;q21) have
better prognosis (22).
There are a number of studies concerning the alternate
translocation in APL; however, little is still known about the
complex variant translocations in APL (22, 23). Both 4, 15,
17, and 15, 16, 17 translocations have been described by other
authors (4, 6, 22, 23), but the translocation found in our patient
involving four chromosomes 4, 15, 16, and 17 has not been
reported before.
In our cohort, additional chromosomal aberrations were
found in 28% of patients with complete cytogenetic analysis,
with the most common trisomy 8 (43%), similarly described
by Cervera et al. (25). All but one patient from that group
remain in CR. The only patient with treatment failure (death
of disease progression after second relapse) was the child with
complex translocation involving chromosomes 4, 15, 16, and
17 with additional material from chromosome 16. Analyzing all
patients with additional chromosomal aberration in the study
group, no differences in the treatment outcome were found
compared to the patients with isolated t(15;17). It was reported
by Cervera et al. that patients with and without additional
chromosomal abnormalities had similar CR rates, and despite
univariate analysis, they showed that additional chromosomal
abnormalities were associated with a lower relapse-free survival
in the LPA99 trial; such association was not present in the LPA96
trial. Neither additional chromosomal abnormalities overall nor
any specific abnormality was identified as an independent risk
factor for relapse in multivariate analysis (25).
In the current study, FLT3-ITD was present in 44% of
patients. This is in accordance with the other studies where
the frequency of FLT3-ITD mutation was 20–46% (26–30). No
differences in WBC at diagnosis and the treatment outcome
were found in patients with and without FLT3-ITD mutation
but analyzed groups were rather small. The prognostic impact
of FLT3-ITD mutation in APL remains controversial. Some
authors describe negative influence on prognosis. Lucena-Araujo
et al. screened for FLT3-ITD mutations in 171 APL patients
(including nine children) and reported that FLT3-ITDmutations
were associated with high WBC counts and may independently
predict a shorter survival in patients with APL treated with
ATRA and anthracycline-based chemotherapy (28). Association
between FLT3-ITD mutation and high WBC was also confirmed
by Barragan et al. in PATHEMA and HAVON groups, but the
study did not demonstrate an independent prognostic value of
FLT3-ITDmutation in patients with APL treated with ATRA and
anthracycline-based regimens (29).
The COG AAML0631 study on childhood APL did not
show an association of FLT3-ITD mutations with early death
or bleeding/clotting events in induction; however, it was
revealed that the relapse rate following ATO consolidation was
significantly higher in FLT3-ITD mutant patients (30).
To conclude, the treatment outcome in children with APL
in Poland is similar to results reported by other study groups.
Reduction of early deaths in the last years was noticed. That
could be the effect of introducing ATRA to a treatment protocol
and the better experience of the study centers in the care for
this challenging group of patients. A new treatment approach
with the use of ATO and ATRA without chemotherapy in the SR
group or with reduced chemotherapy in HR seems to be safe and
effective. The limitation of the study is the relatively low number
of enrolled patients. Further studies are needed to confirm the
results with longer follow-up.
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